background development tolerance following use long acting beta2 agonists asthmatic patients homozygous arginine glycine genotypes poorly documented especially relation acute reliever response salbutamol constricted airways study undertaken evaluate genotypes acute salbutamol response following methacholine bronchial challenge doses formoterol fm salmeterol sm combination inhalers methods parallel groups NUMBER matched homozygous NUMBER homozygous patients completed randomised double blind double dummy crossover study following NUMBER week washout period patients received treatment NUMBER weeks inhaled budesonide bud NUMBER micro g fm NUMBER micro g puffs twice daily inhaled fluticasone propionate fp NUMBER micro g sm NUMBER micro g puff twice daily washouts randomised treatments NUMBER hour inhalation methacholine challenge performed followed salbutamol NUMBER micro g recovery NUMBER minutes primary outcome results washout values forced expiratory volume NUMBER second fev1 methacholine hyperreactivity salbutamol recovery similar treatments genotypes fev1 values genotypes did differ significantly doses treatment salbutamol recovery mean se area NUMBER minute curve significantly delayed p005 equally genotype treatment groups differences salbutamol recovery genotype treatment group conclusion acute salbutamol recovery methacholine constricted airways significantly delayed similar degree genotypes cross tolerance induced fm sm arg NUMBER gly NUMBER arg NUMBER gly NUMBER arg NUMBER gly NUMBER pre challenge time response